PHARMACOVIGILANCE AND REGULATORY ACTION IN EAST AFRICA WITH A FOCUS ON TANZANIA: A SCOPING REVIEW
Universal Journal of Pharmaceutical Research · 15.11.2026
DOI: 10.22270/ujpr.v11i5.1671 ↗Kurz gefasst
Scoping Review in der Zeitschrift Universal Journal of Pharmaceutical Research, online erschienen am 15.11.2026. Verfasst von Lambert Philipo Barugahale und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Pharmacovigilance (PV) detects, assesses and prevents adverse drug reactions (ADRs) and other medicine-related problems. East African countries have built national PV systems, but underreporting and the weak visibility of links between safety information and regulatory decisions persist.
Objectives
To map evidence on PV systems and regulatory action in East Africa with emphasis on Tanzania; to quantify key PV outcomes among health professionals; to identify factors associated with ADR reporting; and to describe how safety information is translated into regulatory action.
Methods
Rapid scoping review following the Arksey and O’Malley framework, Joanna Briggs Institute guidance and PRISMA-ScR reporting, with a conditional quantitative synthesis. Targeted searches of web-indexed biomedical literature, repositories and regulatory and media sources were run in October 2026.
Results
Twenty-five sources were charted: 17 research sources (Tanzania, Uganda, Kenya, Ethiopia, Rwanda and two multi-country studies) and eight regulatory, programme and media reports. In 2017/18, spontaneous reporting was 4.1 reports per million inhabitants in mainland Tanzania, 6.7 in Ethiopia and 35.0 in Kenya, and no more than 1% of facilities submitted reports. Nine surveys of health professionals (n=3,091) gave a pooled ADR-reporting proportion of 30.3% (95% CI 19.1–44.4%; I²=97.9%; 95% prediction interval 4.3–81.0%).
Conclusions
PV structures have advanced and reporting can be raised sharply by training and stimulated reporting, but low and uneven reporting, training gaps and limited visibility of locally triggered regulatory action constrain medicine safety. Peer Review History: Received 25 July 2026; Reviewed 3 September 2026; Accepted 8 October; Available online 15 November 2026 Academic Editor: Dr. Jennifer Audu-Peter, University of Jos, Nigeria, drambia44@gmail.com Reviewers: Dr. Noha El Baghdady, MTI University, Cairo, Egypt, nohasalah21@yahoo.com Dr. Mayada M. El-Azab, Phytochemistry Unit, Department of Medicinal and Aromatic Plants, Desert Research Center, Cairo, Egypt. drmayadaelazab2020@gmail.com
Zitieren
APA
Barugahale, L. P., Lemanya, S. V., Ndetico, K. J., & Mwombeki, L. (2026). PHARMACOVIGILANCE AND REGULATORY ACTION IN EAST AFRICA WITH A FOCUS ON TANZANIA: A SCOPING REVIEW. Universal Journal of Pharmaceutical Research. https://doi.org/10.22270/ujpr.v11i5.1671
Vancouver
Barugahale LP, Lemanya SV, Ndetico KJ, Mwombeki L. PHARMACOVIGILANCE AND REGULATORY ACTION IN EAST AFRICA WITH A FOCUS ON TANZANIA: A SCOPING REVIEW. Universal Journal of Pharmaceutical Research. 2026. doi:10.22270/ujpr.v11i5.1671
BibTeX
@article{Barugahale2026,
author = {Barugahale, Lambert Philipo and Lemanya, Sechelela Vincent and Ndetico, Kennedy John and Mwombeki, Lewis},
title = {PHARMACOVIGILANCE AND REGULATORY ACTION IN EAST AFRICA WITH A FOCUS ON TANZANIA: A SCOPING REVIEW},
journal = {Universal Journal of Pharmaceutical Research},
year = {2026},
doi = {10.22270/ujpr.v11i5.1671}
}
EUVIMED